Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

57.05 -0.14 (-0.24%)
Streaming Delayed Price Updated: 12:21 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Incyte Corp

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Syndax-Incyte Partnered Chronic Graft-Versus-Host Disease Achieves Primary Endpoint In Pivotal Trial, FDA Submission Planned By 2023 End
Syndax Pharmaceuticals (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) announced topline data from the AGAVE-201 trial of axatilimab, in adult and pediatric patients with chronic graft-versus-host... 
Via Benzinga
'I Don't Want You To Touch That': Cramer Rejects Stock Down 32% Over Past Month, Prefers Tesla
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Alexandria Real Estate Equities, Inc. (NYSE: ARE) is "one of the better real estate investment trusts, but I would rather see you in Federal... 
Via Benzinga
Incyte Skin Disease Drug Meets Primary Goal In Late-Stage Study In Children
Incyte Corporation (NASDAQ: INCY) released topline results from its Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream (Opzelura) in children with  
Via Benzinga
Syndax Pharmaceuticals Set for Potential Breakthrough with Revumenib: Analyst Calls It 'Potentially Best-In-Class' In Competitive Landscape
Guggenheim Partners initiated coverage on Syndax Pharmaceuticals Inc (NASDAQ: SNDX) with a BUY rating and a  
Via Benzinga
2 Low-Priced Stocks That Could Make You Richer
These two low-priced healthcare stocks could skyrocket within the next 12 months. 
Via The Motley Fool
Incyte Stock Crumbles As Seasonality Hammers Away At First-Quarter Sales
Incyte's biggest moneymaker, Jakafi, missed first-quarter forecasts. 
Via Investor's Business Daily
Why Incyte Shares Are Falling Today
Incyte Corporation's (NASDAQ: INCY) shares are plunging today after the  
Via Benzinga
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators... 
Via Talk Markets
Market Rally Finishes Strong; Regional Banks, Fed Rate Hike, Jobs Report, Apple In Focus: Weekly Review
The major indexes retreated for most of the week on banking fears, 
Via Investor's Business Daily
Earnings Outlook For Incyte
Via Benzinga
Ominous Death Cross Forms On Incyte's Chart
Via Benzinga
What 13 Analyst Ratings Have To Say About Incyte
Via Benzinga
Incyte Stock Dives On Surprise Rejection For Updated Jakafi
The company had hoped to gain approval for an extended-release version of its biggest drug. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
Via Benzinga
What To Expect When Incyte Reports Q1 Earnings In Almost Two Weeks
Incyte Corporation (NASDAQ: INCY) will report Q1 FY23 results on May 2.  Investor focus remains on the Opzelura launch, which has faced some hiccups over the first 18 months of launch and began to gain... 
Via Benzinga
7 Biotech Stocks That Could Cure Your Portfolio Woes
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill. 
Via InvestorPlace
The Unexpected Way The Texas Abortion Ruling Could Destroy Biotech
One executive called this the most "damaging" decision in five decades. 
Via Investor's Business Daily
Analyst Expectations for Incyte's Future
Via Benzinga
Incyte's Return On Capital Employed Overview
Via Benzinga
Analyst Ratings for Incyte
Via Benzinga
S&P 500 Stocks: Micron, Charles Schwab Among Top Performers Monday
Micron and Charles Schwab were among the top performers. 
Via Investor's Business Daily
Incyte Faces Increased Competition From Emerging JAK Inhibitors, RBC Capital Lowers Price Target
Shares of Incyte Corporation (NASDAQ: INCY) recovered last week, after having been under pressure on setbacks to its LIMBER Program. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 10, 2023
Via Benzinga
Valero Energy To Rally 32%? Here Are 10 Other Analyst Forecasts For Monday
Credit Suisse boosted the price target for The Boeing Company (NYSE: BA) from $200 to $220. Credit Suisse analyst Scott Deuschle maintained a Neutral rating on the stock. Boeing shares fell 0.4% to... 
Via Benzinga
Second Setback For Incyte's LIMBER Program - Analyst Says 'Resolution Timelines Unclear To Assess Impact'
Via Benzinga
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
Via Benzinga
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023. 
Via InvestorPlace
Why Shares of MacroGenics Climbed Thursday
The cancer-focused biotech delivered a strong earnings report. 
Via The Motley Fool
Which S&P 500 Stocks Look Most Attractive Now?
Using ValuEngine’s advanced screening tool, we select 4- and 5-rated stocks in the SPY ETF. As we can see in the table below, 20 stocks passed the screen with two strong buys; CEG and NCLH. 
Via Talk Markets
Incyte Discontinues LIMBER-304 On Doubts Regarding Meeting Primary Goal, Analyst Says It Underpins Some Investor Concerns
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.